Syfovre Retinal Vasculitis Eye Inflammation Side Effects Causing Vision Loss
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are currently investigating Syfovre retinal vasculitis eye inflammation cases as possible Syfovre drug injury lawsuits for patients. These lawsuits would be against Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre.
Syfovre is an eye-injection drug treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It was approved by the FDA on February 17, 2023.
Syfovre side effects include occlusive retinal vasculitis, which is a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and could potentially cause blindness. There have also been reported cases of non-occlusive retinal vasculitis and other types of eye inflammation.
To date, all reported Syfovre adverse events causing these vision problems began one to two weeks after a patient’s first Syfovre injection.
UPDATE: From this February 28, 2024, Fierce Pharma news report, “Apellis cites current challenges with Syfovre launch but bright prospects in the long term“, we get the most recent explanation from Apellis Pharmaceuticals about the cause of Syfovre eye-related side effects:
As for Syfovre’s safety issue — which Apellis originally speculated was a needle problem for the injected drug — the company now “firmly” believes it is caused by a pre-existing allergy toward polyethylene glycol, Francois said. The incidence of users developing vasculitis remains at .01% per injection, the company said. [Emphasis added.]
(2/28/24)
Free Syfovre Case Evaluation
We encourage you to submit a Syfovre Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Syfovre drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his more than 20 years of experience handling drug injury cases.
Most Recent Articles About Syfovre
Syfovre: Loss of Vision 11 Days After Receiving Syfovre Injection
This blog post is about a Syfovre loss of vision case involving a 78-year-old woman with vision loss in the first part of 2023. It was reported in this medical journal article, “Retinal vasculitis following intravitreal pegcetacoplan administration”, which appeared in the March 2024 edition of the American Journal of Ophthalmology Case Reports.
From the Abstract for this relatively recent article about a Syfovre loss of vision case:
To read more of this article, click below:
Purpose: To describe a case of retinal vaso-occlusive vasculitis with associated lid edema and conjunctivitis following intravitreal [Syfovre (pegcetacoplan)] administration in a patient with geographic atrophy (GA).
Observation: A 78 year old Caucasian woman presented with complaints of lid edema, conjunctival injection, loss of vision, and mild ocular discomfort eleven days after receiving an intravitreal [Syfovre (pegcetacoplan)] injection in the left eye for geographic atrophy. Visual acuity on presentation was decreased to 20/400 from 20/200 previously in that eye….
From the Conclusion part of that March 2024 medical journal article about this Syfovre loss of vision case:
Being vigilant after the administration of intraocular pegcetacoplan and encouraging prompt evaluation of patients who present with new symptoms post injection is critical. Prompt treatment with topical, local, systemic corticosteroids is critical to control the inflammatory response to prevent further visual loss.
We are handling Syfovre drug injury lawsuits for people who developed retinal vasculitis or retinal vascular occlusion causing loss of vision or blindness after their Syfovre injection. These Syfovre lawsuits would be filed against Apellis Pharmaceuticals, the drug company responsible for Syfovre — not the person’s eye doctor.
Perhaps you know a person who has had a loss of vision after getting a Syfovre injection in their eye. In that situation, this person must contact a lawyer to handle their Syfovre case to get legal compensation for the Syfovre drug injury they have suffered. Syfovre loss of vision lawsuits are being filed as individual cases. There will not be any Syfovre class actions for people who have experienced any loss of vision due to Syfovre.
[Read article in full at original source]Syfovre Eye Injury Cases Update One Year After First Reports: “Uncertain”
Beginning in April 2023, there have been reports of Syfovre eye injury cases, including retinal vasculitis resulting in significant vision loss. As of the beginning of April 2024, however, retina specialists seem to agree that the number of patients who developed retinal vasculitis after their Syfovre injection remains uncertain.
Put in more simple terms, the cause is still unknown and the number of patients remains unclear when it comes to retinal vasculitis after Syfovre injections.
There are at least two difficulties when determining the number of Syfovre eye injury cases involving retinal vasculitis that have occurred to date:
- It is generally acknowledged that voluntary reporting of prescription drug adverse events is inherently subject to underreporting. Therefore, it is likely that some Syfovre retinal vasculitis cases have not been reported to the FDA, Apellis Pharmaceuticals, or retina specialists; and,
- Some Syfovre patients who developed “mild” retinal vasculitis might not have been identified because they did not receive a careful dilated fundus examination or fluorescein angiography (FA). As such, these patients who might have developed retinal vasculitis are not counted by the Syfovre injections incidence rate.
We are investigating Syfovre drug injury cases for patients who suffered vision loss due to retinal vasculitis after Syfovre injections. These Syfovre lawsuits would be filed against Apellis Pharmaceuticals, not the patients’ ophthalmologists or retina specialists.
To read more of this article, click below:
We have been monitoring this Syfovre drug safety issue and continue to report significant developments on our Drug Injury Watch website. We list our three most recent articles if you want to learn more:
- Syfovre Case Report: Occlusive Retinal Vasculitis Shortly After Patient’s First Syfovre Injection (3/6/2024)
- Syfovre Safety Issues Need More Attention Before This Relatively New Eye Drug Gets Widely Prescribed (12/27/2023)
- Syfovre Update: New Warnings About Retinal Vasculitis and/or Retinal Vascular Occlusion After Syfovre Injections (12/4/2023)
If we can assist you or someone you know, our Syfovre Case Evaluation Form is available online, or you can call us at (800) 426-9535 to speak about a possible Syfovre eye injury case.
[Read article in full at original source]Earlier articles about Syfovre by attorney Tom Lamb on the Side Effects Blog:
- At Least 13 Patients Had Syfovre Retinal-Related Vision Loss in 2023
- Syfovre Side Effects Issue Raised In December 2023 JAMA Viewpoint Piece
- New Syfovre Warnings for Retinal Vascular Occlusion and Retinal Vasculitis
- Syfovre Eye Side Effects Cases Reported at Ophthalmology Meeting
- Syfovre Retinal Vasculitis Cases Caused by Injection Kits With a 19-gauge Filter Needle?
- Syfovre Eye Injections Adverse Reactions Update August 2023
- Syfovre Vision Loss Cases Reported In Patients After First Injection